Cardiol Therapeutics (TSX:CRDL, NASDAQ:CRDL) CEO David Elsley joined Steve Darling from Proactive to share some significant news: the United States Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for the company's lead small molecule drug candidate aimed at treating pericarditis, including recurrent pericarditis. This designation is a major validation of CardiolRx's potential in addressing a debilitating heart condition.
Elsley explained that recurrent pericarditis is a serious heart disease characterized by symptoms that significantly impact patients' quality of life and physical activity. The FDA's decision to grant ODD underscores the potential of CardiolRx to improve the lives of individuals suffering from this condition. MAvERIC-Pilot is a Phase II open-label pilot study investigating the tolerance, safety, and effect of CardiolRx™ administered to patients with recurrent pericarditis. In addition to standard safety assessments, MAvERIC-Pilot is designed to evaluate improvement in objective measures of this rare disease.
Orphan Drug Designation is granted by the FDA to drugs or biological products intended to prevent, diagnose, or treat rare diseases or conditions affecting fewer than 200,000 people in the United States. This designation offers several benefits to sponsors, including potential seven-year marketing exclusivity, exemptions from certain FDA fees, and tax credits for qualified clinical trials. Additionally, products with ODD may qualify for accelerated regulatory review through Fast Track, Breakthrough Therapy, or Priority Review designations.
This milestone represents a significant advancement for Cardiol Therapeutics and its efforts to develop innovative therapies for cardiovascular diseases. With CardiolRx currently in Phase II clinical trials for recurrent pericarditis and acute myocarditis, the ODD from the FDA further strengthens the company's position in advancing treatments for these conditions